Investors

Overview

PATENTS & INTELLECTUAL PROPERTY (IP)

ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine. ACT recently secured a patent on its “embryo-safe” single-blastomere technology and in June of 2010 secured a broad patent for production of RPE cells.

ACT's Clinical Trial for Dry AMD Featured On Bloomberg TV, January 2011. (Coverage of ACT starts at halfway point)